Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Eisai’s Halaven Receives Orphan Drug Designation for Soft-Tissue Sarcoma in US
August 22, 2012
- Pazopanib Approved for aSTS in Europe: GSK
August 22, 2012
- Oncology Japan 2012 to Be Held on November 7, 8
August 22, 2012
- Mediscience Stepping Up Athlete Recruitments as CMRs
August 21, 2012
- ARB Prescription Rate Affected by Doctors’ Evaluations of MRs: M3 Survey
August 21, 2012
- Generic Actos Launched in US; Takeda Grants AG to Teva, Ranbaxy
August 21, 2012
- Astellas to Build New Building to Boost Production Capacity of Investigational Anticancer Drug Substances
August 21, 2012
- DSP to Set Up Cancer Institute Led by CEO of Its US Subsidiary BBI
August 21, 2012
- Synagis IM Liquid Injection Solution Approved: Abbott Japan
August 20, 2012
- Pfizer Terminates Development of AD Treatment Bapineuzumab
August 20, 2012
- RIBOMIC Acquired Patent for Analgesic Agent Containing Aptamer
August 20, 2012
- “Sense of Achievement” Motivates MRs; Brach Managers to Be Blamed for Miscommunications: Survey of Managers
August 20, 2012
- OncoTherapy Confirms Safety of OCV-C01 for Pancreatic Cancer in PIII Trial
August 17, 2012
- Mizuho Forecasts Sales Increases and Falling Profits in FY2012 for 9 Major Domestic Pharmaceutical Manufacturers
August 17, 2012
- Bonac Confirms Safety of RNAi Agents for Pulmonary Fibrosis in Animal Studies
August 17, 2012
- “Character” Tops List of Traits Doctors Require of MRs: MREAC Survey
August 17, 2012
- Higher Dose of Methotrexate Approved: Pfizer
August 17, 2012
- Teijin Pharma Obtains Approval for Bonalon Jelly
August 16, 2012
- Humira Can Be Used for RA Patients without Treatment History: Abbott, Eisai
August 16, 2012
- Eisai’s US Subsidiary Morphotek Opens New Antibody Production Plant
August 16, 2012
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…